Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma (NCT06580223) | Clinical Trial Compass
Not Yet RecruitingPhase 3
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
China530 participantsStarted 2025-09-01
Plain-language summary
The aim of this study is to evaluate the efficacy and safety of aspirin and rivaroxaban in thromboprophylaxis in Chinese MM patients at high risk for MM-associated VTE.
Who can participate
Age range18 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Newly diagnosed multiple myeloma (according to Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision))
✓. High risk of VTE (according to Expert consensus on the prevention and treatment of multiple myeloma related venous thromboembolism in China (2022))
✓. Life expectancy exceeding 12 months
✓. Gender: not specified, Age: 18-90 years
✓. Serum HIV antigen or antibody negative
✓. HCV antibody negative, or HCV antibody positive with HCV RNA negative
✓. Echocardiogram shows a left ventricular ejection fraction of ≥50%
✓. Ability to sign an informed consent form
Exclusion criteria
✕. Pregnant women or women who are breastfeeding
✕. Active gastrointestinal ulceration
✕. Active bleeding
✕. When initiating treatment, platelet count below 50 G/L, or with PT prolonged by more than 3 seconds, and APTT prolonged by more than 10 seconds.
✕. Abnormal liver function (ALT or AST greater than 3 times the upper limit of normal, or total bilirubin greater than 2 times the upper limit of normal)
What they're measuring
1
Incidence of VTE within 6 months
Timeframe: 6 months
Trial details
NCT IDNCT06580223
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology